Endothelin-1 stimulates cytosolic phospholipase A2 activity and gene expression in rat glomerular mesanglal cells. Endothelin-i (ET-1) stimulates vascular smooth muscle and mesangial cells to release prostaglandin E2 (PGE2), which can attenuate the vasoconstrictor and mitogenic effects of this peptide. Phospholipase A2 (PLA2)-mediated release of arachidonic acid from the sn-2 position of membrane phospholipids is thought to be one of the rate-limiting steps in prostaglandin (PG) synthesis. We evaluated the role of ET-1 to regulate gene expression, protein synthesis and enzymatic activity of cytosolic PLA2 (cPLA2), an intracellular form of the PLA2 enzyme family, in cultured rat mesangial cells using both acute and chronic incubation protocols. Acute ET-1-induced stimulation of cPLA2 activity was maximal after 10 minutes (181.1 6.84% of control), persisted for 40 minutes and did not require new protein synthesis. Heparin, a potent inhibitor of intracellular Ca2 increase as well as mitogen-activated protein (MAP) kinase activation and cell proliferation, did not affect the rapid cPLA2 stimulation by ET-1. Chronic incubation of glomerular mesangial cells with FT-i (ito 24 hr) led to time-and dose-dependent increases in cPLA2 mRNA expression which Endothelin-1 (ET-1) is a vasoactive and mitogenic peptide, which has diverse effects on kidney function and mesangial cell biology [1] . Nanomolar or higher concentrations of this peptide induce potent and long lasting vasoconstrictor effects in most vessels of the cardiovascular system. Bolus administration of ET-1, however, leads to a biphasic blood pressure response consisting of an initial, transient depressor response, followed by a marked and sustained pressor
was maximal after six hours, persisted up to 24 hours and which was accompanied by both cPLA2 protein formation, as assessed by Western analysis, as well as by stimulation of enzymatic activity. Inhibition of protein synthesis by cycloheximide increased basal cPL.A2 mRNA accumulation in quiescent mesangial cells, and the combination of FT-i and cycloheximide resulted in a greater induction of cPLA2 gene expression when compared to ET-1 alone. Actinomycin D treatment blocked the effect of ET-1 on cPLA2 mRNA accumulation. Herbimycin A, an inhibitor of cellular protein tyrosine kinases, abrogated the FT-i-induced cPLA2 gene expression, while protein kinase C (P1(C) inhibitors (Calphostin, Sangivamycin) only slightly reduced cPLA2 mRNA, We thus conclude that ET-1 is able to stimulate cPLA2 in a biphasic manner: Acute stimulation starts after five minutes and does not require de novo protein synthesis, while long-term activation after three hours is most likely linked to cPLA2 gene expression via a cellular tyrosine kinase pathway. FT-i-mediated acute and chronic stimulation of cPLA2 could serve as an autocrine and/or paracrine negative regulator for vasoconstrictive and mitogenic effects of ET-1.
In the kidney, intravenous and intra-arterial infusion of ET leads to an intense, dose-dependent renal vasoconstriction accompanied by substantial reductions of renal blood flow (RBF), glomerular filtration rate (GFR) and urine flow rate as well as an increase of renal vascular resistance [5, 6] . The reduction of GFR seen at higher ET doses can be caused by the contraction of intraglomerular mesangial cells, which seem to reduce the gbmerular capillary surface area available for ultrafiltration, thereby leading to a dramatic fall in the glomerular ultrafiltration coefficient (Kf) [7] . Similar to the systemic response, transient renal vasodilation often precedes vasoconstriction induced by ET [3] .
Inhibition of PG synthesis partially prevents the early renal vasodilatation induced by ET, thereby potentiating the decline in RBF and GFR [8] . Renal venous and arterial as well as urinary 6-ketoprostaglandin F1 increase after ET infusion [8] . Thus, the renal hemodynamic effects of ET are significantly influenced by its ability to enhance production of vasodilatory PG.
Prostaglandin E2 (POE2) and 12 (PGI2) formation are the result of similar sequential enzymatic activities: phospholipase A2 (PLA2), prostaglandin endoperoxide synthase (PGHS) and PGE2 or PGI2 synthase [9] . The rate limiting step in PG synthesis seems to be the phospholipase A2 (PLA2)-mediated release of arachidonic acid from the sn-2 position of membrane phospholipids [reviewed in 10] . Phospholipases A2 comprise a family of enzymes and can be subdivided into secretory and intracellular forms [10, 11] . One group contains different secretory phospholipases A2 (5PLA2), which have molecular masses in the range of about 14 kDa with seven disulfide bonds, depend upon millimolar concentrations of calcium for maximal activity and do not demonstrate preference for the fatty acid present in the sn-2 position of phospholipids. Another form, an intracellular, high-molecular weight cytosolic phospholipase A2 (cPLA2), which is hormonally regulated, dithiothreitol-insensitive and which depends upon micromolar concentrations of calcium for maximal activity, has been identified in glomerular mesangial cells and the human monocyte cell line U937 [12] [13] [14] and has been purified from pig spleen, bovine lung and bovine kidney [15] . Furthermore, a eDNA encoding a 85.2 kDa PLA2 protein, which lacks any identity with sPLA2 cDNA's, has been cloned recently [16, 17] .
Although it is well known that cPLA2 can be rapidly activated by different agonists in glomerular mesangial cells [12, [18] [19] [20] , only indirect evidence exists for a role of cPLA2 in ET-1-induced postreceptor signaling. In mesangial and endothelial cells, for example, ET-1 has been reported to induce release of both PGE2 and stable metabolites of PG!2 or TXA2 [21] [22] [23] [24] . An ET-1-stimulated [3H]arachidonic acid release has been shown in vascular smooth muscle cells [25, 26] , glomerular mesangial cells [21] and, more recently, in Chinese hamster ovary (CHO) cells stably expressing the bovine ETA or the rat ETB receptor [27}. Beyond that, using CHO cells stably expressing either the human ETA or ETB receptor, we were able to directly measure an ET-1-stimulated rapid increase in cPLA2 activity through both ET receptors [28] .
Compared to the acute stimulation of cPLA2, less is known about the regulation of cPLA2 gene expression. To date agonistinduced cPLA2 gene expression has only been reported for cytokines [20, 29, 30] , EGF [31] , macrophage colony-stimulating factor [32] and PMA [31] , but not for G-protein-coupled agonists.
For these reasons we have investigated the ET-1-induced activation of cPLA2 in mesangial cells as well as the underlying mechanisms of its acute and chronic regulation. We now report that ET-1 rapidly increases cPLA2 activity without de novo protein synthesis. Long-term incubations in the presence of ET-1, however, induce cPLA2 mRNA expression, which is accompanied by an increase in protein mass as well as enzymatic activity. This ET-1 stimulated cPLA2 mRNA expression occurs via tyrosine phosphorylation signaling cascades.
Methods

Mesangial cell culture
Glomerular mesangial cells (GMC) from male Sprague-Dawley rats were isolated and characterized as reported previously [33] . Cells were maintained in RPMI 1640 medium supplemented with 17% fetal bovine serum (FBS), 100 U/mi penicillin, 100 tg/ml streptomycin, 5 gJml each of insulin (I) and transferrin (T), and 5 ng/ml of selenite (S) at 37°C in a 5% CO2 incubator. GMC in passages 10 to 20 were employed in this study.
Experimental protocols
For short-term incubations (time points 5, 10, 20 and 40 mm), confluent GMC (passage [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] were placed in FBS-and ITS-free RPMI 1640 for two hours prior to the experiment. ET-1 or carrier were then added directly to the media. For long-term incubations (1, 3, 6, 9, 12 and 24 hr) GMC were made quiescent for 24 hours in FBS-and ITS-free RPMI 1640. Thereafter, media were changed and agonists or carrier were added to this fresh FBS-and ITS-free RPMI 1640. After various times of incubation, cells were used for measurements of PLA2 activity as well as for Western blot or Northern blot analysis.
PIA2 activity assay PLA2 activity was assayed according to a method recently published elsewhere [12, 28] . After the respective incubation protocols GMC were rinsed three times and scraped at 4°C into a homogenization buffer containing 50 mrvi HEPES (pH 7.4), 250 m sucrose, 1 mM EGTA, 1 mrvi EDTA, 1 j.tg/ml leupeptin, 1 g/ml pepstatin, 0.1 mivi PMSF and 1,000 kallikrein-inactivating U/mi Trasyioi. After cells were homogenized with 25 strokes in a tight Dounce homogenizer, nuclei and debris were removed by centrifugation at 500 x g for five minutes. The low speed supernates were spun at 200,000 X g for one hour in a Beckman ultracentrifuge with a Ti-70. 1 rotor. The high-speed supernates from control and agonist-stimulated cells were matched for protein concentration by appropriate dilution and assayed for cPLA2 activity using [14Cjarachidonyl-phosphatidylcholine as a substrate. The radiolabeled phospholipid substrates were dried down under argon and dissolved in dimethyl sulfoxide. Two microliters of substrate (final concentration, 15 M) were pipetted into an Eppendorf microcentrifuge tube. Reactions were initiated by the addition of 34 pA of cell extracts as well as by addition of an assay buffer containing 5.0 mivi CaCl2 and 50 mrvi HEPES, pH 7.5 (final concentrations); the reaction mixture was incubated for 30 minutes at 37°C. The reaction was terminated by the addition of 40 pA of 2% acetic acid in ethanol, containing 10 tg unlabeled arachidonic acid. Release of free fatty acid was analyzed using silica gel thin layer chromatography plates (LK5D, Whatman). Fifty microliters of the reaction mixture and appropriate standards were spotted onto heat-activated plates and developed in the organic phase of ethyl acetate:isooctane:H20:acetic acid, 55:75:100:8. Lipids were visualized by 12 staining. The free arachidonic acid band was scraped and quantified by scintillation counting. Each assay was performed in triplicate. Blank samples contained no cell extract. cPIA2 activity was expressed as % of control.
Western blot analysis
Total mesangial cell lysates were separated on SDS-10%PAGE, transferred to nitrocellulose paper, and blotted with a specific anti-cPLA2 antibody [15] . The primary antibody (1/1000-diluted antiserum) was detected using horseradish peroxidase-conjugated goat anti-rabbit IgG visualized by Amersham ECL system after intensive washing of the sheets. An equal number of cells was loaded in each lane and equal protein loading was verified by staining blots with Ponceau solution.
RNA extraction and Northern RNA blot analysis Total cellular RNA was isolated by the acid guanidium thiocyanate-phenol-chloroform procedure of Chomczynski and Sacchi [34] . The quality of RNA was assessed by measuring the 260 nm/280 nm ratio and determining the ratio of 28S:18S rRNA (2:1) in ethidium-stained denaturing agarose gels. For Northern analysis RNA was denatured by heating for 15 minutes at 65°C in 0.02 M 3-[N-morpholino]propanesulfonic acid, 6.6% formaldehyde, and 50% formamide and fractionated by electrophoresis through a 1.2% agarose gel. The RNA was transferred to nitrocellulose and hybridized with the 2.7 kb human cPLA2 cDNA insert [16] labeled by nick translation with [y-32P]dCTP (New England Nuclear). After hybridization overnight the membranes were washed twice with 2 x SSPE-0.1% SDS at 25°C for 15 minutes and once with 0.2 X SSPE-O.1% SDS at 42°C for 10 minutes and exposed to Fuji RX medical X-ray film at -70°C with intensit'ing screens. After stripping each blot and exposing for 24 hours to ensure complete removal of the probe, the filter was rehybridized with a nick-translated glyceraldehyde phosphate dehydrogenase (GADPH) cDNA probe. cPLA2 hybridization signals were quantified by scanning densitometry and divided by the fold increase in 
Results
ET-1 rapidly activates cPLA2 in GMC
Using a direct measurement of enzymatic activity and CHO cells stably expressing either the human ETA or ETB receptor, we have recently demonstrated that ET-1 is able to stimulate cPLA2 via both ET-receptor subtypes [281. We now report that ET-1 also leads to a rapid, time-dependent ( Fig. 1A ) and dose-dependent ( Fig. 1B ) activation of this enzyme in GMC. As shown in Figure  1A , stimulation of GMC cPLA2 by 100 nM ET-1 occurred after five minutes (146.7 7.87% of control; N = 3), was maximal after 10 minutes (181.8 5.03% of control; N = 8) and persisted up to 40 minutes (174.0 6.69% of control; N = 3). When GMC were incubated for 10 minutes in the presence of different ET-1 concentrations, maximal activation of cPLA2 occurred at 1O M ET-1 (183.0 8.96% of control; N = 5; Fig. 1B ). Incubation of cytosolic extracts with 5 mivi Dfl for 10 minutes at room temperature did not attenuate the ET-1-induced increase in PLA2 activity (data not shown), suggesting that the cytosolic not secretory form of PLA2 is involved in this response. As a positive control, extracts of GMC were stimulated with 100 n PMA for 20 minutes. In accordance with previous reports [12, 20j , PMA led to a 241. 1 15.40% (N = 4) increase in cPLA2 activity. These results provide evidence that ET-1 can rapidly activate cPLA2 in GMC.
Regulation of acute cPLA2 activation by ET-1
To determine the potential mechanisms which could result in an acute enhancement of cPLA2 activity we next performed both Northern and Western blot experiments (Fig. 2) . As shown in Figure 2A , 100 nivi ET-1 had no effect on cPLA2 mRNA expression in GMC during the first 40 minutes. In parallel, ET-1 did not induce cPLA2 protein expression as shown by immunoblot (Fig.  2B) . These results indicate that the rapid stimulation of cPLA2 activity by ET-1 in GMC is most likely due to post-translational modifications of the enzyme rather than to increases in gene expression and enzyme mass.
In GMC ET-1 is a potent stimulus for both p42 and p44 mitogen-activated protein (MAP) kinase [35] , and it was recently reported by two laboratories that p42 MAP kinase can phosphorylate and activate cPLA2 in vitro [36, 37] . In order to find evidence for this interaction in intact GMC we investigated the effects of heparin on ET-1-induced cPLA2 stimulation. Heparin has been shown to partially inhibit ET-1-induced MAP kinase activation in GMC [381. Confluent GMC were placed in FBS-and ITS-free RPMI 1640 for two hours prior to the experiment and then stimulated for 10 minutes with 100 nivi ET-1, either in the absence or in the presence of 2 U/ml heparin (2 hr preincubation). When compared to ET-1 alone (164.1 10.1% of controls; N = 3), preincubation with heparin for two hours did not alter ET-1induced cPLA2 activation (160.6 7.0% of controls; N = 3). Incubation of GMC in the presence of heparin alone did not affect synthase-2 (PGHS-2) expression [39] supports a role for PG's to basal cPLA2 activity (111.3 7.4% of control; N = 3). serve as a long-term autocrine and/or paracrine regulator for vasoconstrictive and mitogenic actions of ET-1. In the present ET-l increases expression of cPLA2 rnRNA and protein mass at study we therefore investigated whether or not ET-1 can also later time points chronically up-regulate cPLA2. One hundred nanomoles of ET-1 Our recent finding that ET-induced release of PGE2 by GMC were added to quiescent GMC for different periods of time and over 6 to 24 hours is a result of prostaglandin endoperoxide total RNA or total cell lysates were analyzed by Northern or Time, hours Hybridization signals were quantified by scanning densitometry and divided by the fold increase in GADPH mRNA from the same blot. cPLA2 mRNA fold increase is shown at the bottom of the blot.
Western blots, respectively. A time-dependent increase in cPLA2 mRNA expression was seen with the earliest increase occurring within three hours of ET-1 treatment (Fig. 3A) . After six hours, a 2 to 2.5-fold increase in steady-state mRNA levels was consistently observed, which was maintained for up to 24 hours. This ET-1-induced increase in cPLA2 mRNA expression was accompanied by an increase in both cPLA2 protein mass ( Fig. 3B ) and enzymatic activity (Fig. 3C ). While an increase in protein mass was detected at six hours and was maximal at 12 hours, cPLA2 activity was significantly elevated after six hours (141.6 4.7% of control; N = 3) and remained increased for up to 24 hours (135.1 2.6% of control; N = 3). These results indicate that cPLA2 mRNA levels can be up-regulated by ET-1 and that this augmented mRNA expression is accompanied by an increase in both cPLA2 protein mass and enzymatic activity.
ET-1 induced cPLA2 mRNA expression shows dose-dependency and inhibition by actinomycin D but not by cycloheximide
As shown in Figure 4 , ET-1, when incubated for six hours, led to a dose-dependent increase in cPLA2 mRNA expression with a threshold at i0 M and a maximal stimulation at i0 M. The mRNA induction by 100 nrvi ET-1 at six hours was blocked by actinomycin D (5 tg/ml, 1 hr preincubation), an inhibitor of transcription (Fig. 5 ). The translational inhibitor cycloheximide (10 .tg/ml, 1 hr preincubation), on the other hand, increased cPLA2 mRNA levels in unstimulated control as well as in ET-1-stimulated GMC (Fig. 5) . When administered alone, acti- ET-1-induced cPL42 mRNA levels. Incubation of quiescent mesangial cells was carried out for 6 hours with ET-! (l0-M) alone, CHX (10 j.tg/ml) alone, CHX (preincubated for 1 hr) plus ET-1, Act.D (5 sWml) alone or Act.D (preincubated for 1 hr) plus ET-1 and compared to unstimulated controls. One of 3 representative experiments is shown. Hybridization signals were quantified by scanning densitometry. cPLA2 mRNA fold increase is shown at the bottom of the blot. nomycin D did not affect basal cPLA2 expression. These results suggest that cPLA2 is present in GMC as an inducible gene.
Furthermore, these data are consistent with the idea that the ET-1 effect is mediated at the transcriptional level.
gene expression
We next examined the role of protein kinase C (PKC) and protein tyrosine kinases (PTK5) in ET-1-stimulated cPLA2 mRNA accumulation (Fig. 6 ). To determine whether PKC and/or PTK mediate induction of cPLA2 mRNA by ET-1 in GMC, we evaluated the effects of two PKC inhibitors (caiphostin, sangivamycin) and two PTK inhibitors (herbimycin A, genistein). While pretreatment of quiescent GMC for one hour with 100 nvi calphostin only slightly decreased ET-1-stimulated cPLA, mRNA expression, preincubation with 1 I.tM herbimycin A, a potent inhibitor of cellular PTKS, completely abolished ET-1-induced cPLA2 gene expression ( Fig. 6 ). Compared to caiphostin, qualitatively similar results were obtained when quiescent GMC were pretreated for one hour with the PKC inhibitor sangivamycin (100 nM) ( Fig. 7) . Genistein (6 xWml), a potent inhibitor of ATP binding site of PTKs, also inhibited cPLA2 mRNA expression by ET-1 although to a lesser extent than herbimycin A (Fig. 7 ).
Together these findings indicate that activation of cellular PTKS is a necessary signaling pathway through which ET-1 stimulates cPLA2 mRNA expression. An involvement of PKC in ET-1regulated cPLA2 mRNA expression, however, cannot be excluded. 
Discussion
We have made parallel evaluations of cPLA2 mRNA expression, protein formation and enzymatic activity in GMC and have investigated the acute and chronic regulation of this enzyme by a U-protein-coupled vasoactive and mitogenic peptide, namely endothelin-l (ET-1). ET-1 rapidly stimulated cPLA2 activity in GMC which did not require new protein synthesis. This result is in accordance with previous studies showing that, in glomerular mesangial cells, cPLA2 can be acutely activated by different agonists, such as arginine vasopressin (AVP), phorbol myristate acetate (PMA), epidermal growth factor (EGF) [12, 40}, interleu- kin-la (IL-la) [20] , interleukin-1f3 (IL-113) and transforming growth factor-2 (TGF-132) [19] . For most of these agonists it has been reported that the acute increase in cPLA2 activity is due to a stable post-translational modification of the enzyme [12, 20, 40] . Stimulation of cPLA2 also demonstrates a dependency on intracellular Ca2 that is compatible with physiologic regulation by Ca2 in intact cells [10] . An agonist-stimulated increase in intrinsic cPLA2 activity is only apparent when a rise in cytosolic Ca2 allows translocation of the enzyme to its substrate [10, 12, 16] . However, the catalytic domain of cPLA2 seems to function independently of the Ca2-dependent lipid-binding domain, which is necessary for association of cPLA2 with its aggregated substrate [41] . Although we were not able to detect a band-shift in immunoblots as an indication for phosphorylation of this enzyme, it is most likely that phosphorylation is also involved in the rapid stimulation of cPLA2 by ET-l. Recent in vitro experiments have indicated that both protein kinase C and MAP kinase can phosphorylate and activate cPLA2 [36, 37] . It has been also reported that heparin, which has several biological effects including inhibition of increments of cytosolic Ca2, reduction of c-fos [42] and antagonism of cell proliferation [43] , can inhibit MAP kinase in smooth muscle cells [44] . Furthermore, our group has recently shown that this complex glycosaminoglycan completely abolished PGE2-induced MAP kinase activity and significantly inhibited ET-1-induced but not EGF-stimulated MAP kinase activity in GMC [38] . In the present study we now report that heparin did not have any effect on ET-l stimulated cPLA2 activity in intact glomerular mesangial cells. Together with the finding that PGE2 can stimulate MAP kinase but not cPLA2 activity in GMC [38] these findings suggest that in intact GMC MAP kinase is not the only intracellular signal necessary for activation of cPLA2, Besides this rapid ET-1-induced stimulation, our chronic incubation experiments reveal that, in addition to the growing list of cytokine- [20, 29, 30] and growth factor- [31, 32] activated receptors, G-protein-coupled receptor agonists are able to upregulate cPLA2 gene expression as well. The time-and dosedependent cPLA2 mRNA expression by ET-1 is accompanied by protein formation, as assessed by Western analysis, and corresponds to directly measured enzymatic activity suggesting that newly synthesized GMC cPLA2 is also biologically active. It is important to note, however, that this chronically stimulated cPLA2 activity most likely reflects a combination of both posttranslational events as well as an increased abundance of cPLA2 protein. While the fact that actinomycin D inhibited cPLA2 mRNA accumlation in ET-1-stimulated mesangial cells is consistent with an ET-1 effect mediated at a transcriptional level, a nuclear run-off analysis would be necessary to definitely confirm this result. Cycloheximide increased cPLA2 levels in unstimulated control cells and, when incubated together with ET-1, led to a 2.8-fold increase in cPLA2 mRNA expression. Cycloheximide has previously been shown to superinduce immediate early-response genes, including c-fos, c-jun and c-myc by alteration in mRNA stability in transcripts with AUUUA repeats in 3'-untranslated regions of the mRNA [45] . Recently, superinduction of EGFinduced cPLA2 gene expression by cycloheximide has been reported in glomerular mesangial cells [31] and multiple conserved AUUUA sequences in the 3'-untranslated region of human and murine cPLA2 have been identified [16] . Besides its possible effect on cPLA2 mRNA stability, cycloheximide might also inhibit the translation of transcription factors which normally provide basal inhibition of cPLA2 gene expression and thereby lead to superinduced gene expression.
We also performed experiments to determine the role of protein kinase C (PKC) and protein tyrosine kinases (PTK) in ET-1-stimulated cPLA2 gene expression. In comparison to PKC inhibitors, which only slightly reduced cPLA2 mRNA induction by ET-1, the cellular PTK inhibitor herbimycin A completely abolished this ET-1 response. These results are in line with recent studies, which have suggested that vasoconstrictor peptides can activate both PKC and non-receptor-linked tyrosine kinase activities [46, 47] . In GMC, PKC was shown to be necessary but not sufficient for mitogenic signaling by ET-1 [47] . In addition, PTK activity was required for induction of c-fos, AP-1 DNA binding activity, and AP-1 cis-element activity by ET-1 [47] . Furthermore, analysis of the 5' flanking region of the rat cPLA2 gene revealed multiple potential AP-1 binding sites as well as an NFkB consensus sequence [48] . We thus speculate that ET-1 regulates transcription factors in a PTK-sensitive way, and that this might be one mechanism by which ET-1 activates cPLA2 mRNA expression. Alternatively, a tyrosine kinase may regulate phosphorylation of a cytoplasmic protein which binds to the 3' untranslated region and stabilizes cPLA2 mRNA.
Together these results are consistent with the idea that ET-1 regulates cPLA2 both acutely as well chronically. This biphasic stimulation most likely involves different mechanisms, the rapid cPLA2 activation being mainly post-translationally regulated, while the chronic cPLA2 stimulation also occurring at a transcriptional level. In support of earlier reports [1, 3, 4, 9, 24, 28, 39] , we suggest that ET-1-induced short-term and long-term activation of cPLA2 plays an important role in the ET-1-mediated release of PGs and thereby may serve as an autocrine and/or paracrine negative regulator for vasoconstrictive, mitogenic and inflammatory stimuli. Moreover, these results are in line with our recent experiments showing that ET-1 induces prostaglandin endoperoxide synthase-2 (PGHS-2) mRNA expression, protein formation and bioactivity [39] , thereby enhancing cellular capacity not only to release arachidonic acid but also to convert arachidonate to biologically active PGs such as PGE2.
